Tesamorelin + Ipamorelin 10/5 mg

Tesamorelin + Ipamorelin for research: identity and specifications

This product is a two-compound blend supplied in a single vial: 10 mg of tesamorelin and 5 mg of ipamorelin, as a lyophilized powder with no fillers, carriers or excipients. It pairs a stabilized growth hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue receptor (GHS-R1a) agonist for combined in vitro research on the somatotropic axis, at ≥98% purity by HPLC with the lot-specific value reported on the certificate of analysis. Both peptides are synthesized by solid-phase peptide synthesis (SPPS) and purified by HPLC.

Scientific background

Tesamorelin is a synthetic 44-amino-acid GHRH analog carrying an N-terminal trans-3-hexenoyl group that protects it against rapid cleavage by dipeptidyl peptidase-IV. Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that binds the GHS-R1a (ghrelin) receptor. In experimental models, the two act on different receptors of the somatotropic axis.

The blend is used in cell-based and preclinical research on pituitary signaling, receptor selectivity and peptide-receptor interactions, always under controlled bench conditions and without extrapolating results to human or veterinary use.

• Signaling of a stabilized GHRH analog (tesamorelin)
• Selective GHS-R1a agonism (ipamorelin)
• Peptide-receptor interactions of the somatotropic axis in vitro
• Peptide stability and degradation assays

Technical specifications

Analytical quality and chain of custody

Every lot of this blend is synthesized in registered facilities, with independent analytical verification by third-party laboratories and full chain-of-custody documentation. The certificate of analysis (COA) for each lot can be reviewed before purchase, recording HPLC purity and the other quality-control parameters used to release the material.

Reconstitution and laboratory handling

As a bench procedure, the lyophilized vial is reconstituted with a known volume of a suitable solvent, added along the inner wall of the vial, followed by gentle swirling until fully dissolved, without vigorous shaking. Because both peptides share the vial, the concentration of each is calculated from the amounts stated above. The reconstituted solution should be kept refrigerated and protected from light, and used in controlled assays within the stability period validated by the laboratory. Handling must be performed only by qualified personnel, in a bench environment suitable for in vitro experimentation, with lot number and storage conditions documented according to good laboratory practice.

Frequently asked questions

What is the purity of the blend?

≥98% by HPLC, with the lot-specific value reported on the certificate of analysis (COA).

What does the vial contain?

10 mg of tesamorelin (PubChem CID 16137828) and 5 mg of ipamorelin (PubChem CID 9831659), together in one lyophilized vial.

How should the product be stored?

At -20 °C, protected from light and moisture, as a lyophilized powder until reconstitution.

Does the certificate of analysis come with the lot?

Yes, every lot has a matching COA that can be verified before purchase using the button on this page.

Who can purchase this blend?

Sales are restricted to qualified researchers and institutions, for laboratory use only, as detailed in the research-use-only notice on this page.

See the peptide reference guide, the page on how every lot is tested by HPLC and COA and the molecular structures of tesamorelin and ipamorelin in the PubChem database.

Research use only (RUO). This material is supplied for in vitro laboratory research only. It is not a drug, dietary supplement or cosmetic, and it is not intended for human or veterinary use, or for the diagnosis or treatment of any condition. Sales are restricted to researchers and institutions.